1. Plasminogen activator inhibitor-1 promoter polymorphism is not associated with the aggressiveness of disease in prostate cancer.
- Author
-
Li H, Shinohara ET, Cai Q, Chen H, Courtney R, Cao C, Wang Z, Teng M, Zheng W, and Lu B
- Subjects
- Aged, Aged, 80 and over, Genotype, Humans, Male, Middle Aged, Prognosis, Prostatic Neoplasms pathology, Risk Assessment, Risk Factors, Neoplasm Recurrence, Local genetics, Plasminogen Activator Inhibitor 1 genetics, Polymorphism, Genetic, Promoter Regions, Genetic genetics, Prostatic Neoplasms genetics
- Abstract
Aims: PAI-1 (plasminogen activator inhibitors-1) regulates plasminogen activation, and is related to tumour development. This study aims to test whether the promoter polymorphism in the PAI-1 gene is related to the aggressiveness of disease in prostate cancer., Materials and Methods: In the present study, Taqman SNP genotyping assay was used to detect PAI-1 4G/5G polymorphism in DNA from paraffin-embedded tissues of 98 Caucasian patients with prostate cancer., Results: The distribution of the genotypes is in Hardy-Weinberg equilibrium. The genotype had no statistically significant relationship with other prognostic factors. Similar risks for recurrence were seen in individuals with the 4G/4G and 4G/5G genotypes compared to those with 5G/5G genotype (odds ratio [OR] 2.65, 95% CI: 0.41-16.94, P = 0.30; OR = 2.19, 95% CI: 0.38-12.49, P = 0.38)., Conclusion: We concluded that PAI-1 promoter polymorphism is not associated with the aggressiveness of disease in prostate cancer.
- Published
- 2006
- Full Text
- View/download PDF